BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 23774078)

  • 1. HPV testing and vaccination in Europe.
    Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
    J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
    Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
    Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Can human papillomavirus testing and vaccination prevent cervical cancer?].
    Lie AK; Bjørge T; Helland A; Hagen B; Skjeldestad FE; Hagmar B; Thoresen S
    Tidsskr Nor Laegeforen; 2001 Oct; 121(25):2947-51. PubMed ID: 11715778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing.
    Sherman ME; Schiffman MH; Lorincz AT; Herrero R; Hutchinson ML; Bratti C; Zahniser D; Morales J; Hildesheim A; Helgesen K; Kelly D; Alfaro M; Mena F; Balmaceda I; Mango L; Greenberg M
    Cancer; 1997 Apr; 81(2):89-97. PubMed ID: 9126136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus testing for primary cervical cancer screening.
    Grce M; Davies P
    Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
    Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
    BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: a retrospective review of the Southern California Permanente Medical Group experience.
    Lonky NM; Mahdavi A; Wolde-Tsadik G; Bajamundi K; Felix JC
    J Low Genit Tract Dis; 2010 Jul; 14(3):200-5. PubMed ID: 20592555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
    Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
    Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-risk human papillomavirus detection in women with low-grade squamous intraepithelial lesions or higher-grade cytology using the Cervista HPV HR test.
    Gold MA; Thomas MA; Huh WK; Sarto GE; Day SP
    J Low Genit Tract Dis; 2013 Jan; 17(1):51-7. PubMed ID: 22885641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for cervical cancer: new alternatives and research.
    Lörincz AT
    Salud Publica Mex; 2003; 45 Suppl 3():S376-87. PubMed ID: 14746031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
    Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
    Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
    BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triage human papillomavirus testing for cytology-based cervical screening in women of different ages in primary hospitals: A retrospective clinical study.
    Zhang YY; Xu XQ; Zhang D; Wu J; Zhang HX
    Medicine (Baltimore); 2020 Sep; 99(38):e22320. PubMed ID: 32957398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Options for triage and implications for colposcopists within European HPV-based cervical screening programmes.
    Leeson S; Alalade R; Singh N; Nieminen P; Cruickshank M; Carcopino X; Bergeron C
    Eur J Obstet Gynecol Reprod Biol; 2021 Mar; 258():332-342. PubMed ID: 33524777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
    El-Zein M; Richardson L; Franco EL
    J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
    Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.